1
|
He A, Ma L, Huang Y, Zhang H, Duan W, Li Z, Fei T, Yuan J, Wu H, Liu L, Bai Y, Dai W, Wang Y, Li H, Sun Y, Wang Y, Wang C, Yuan T, Yang Q, Tian S, Dong M, Sheng R, Xiang D. CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life Sci Alliance 2020; 3:3/5/e202000648. [PMID: 32234750 PMCID: PMC7119369 DOI: 10.26508/lsa.202000648] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/18/2020] [Accepted: 03/19/2020] [Indexed: 12/31/2022] Open
Abstract
Osteosarcoma (OS) is a primary malignant bone neoplasm with high frequencies of tumor metastasis and recurrence. Although the Akt/PKB signaling pathway is known to play key roles in tumorigenesis, the roles of cyclin-dependent kinase-like 3 (CDKL3) in OS progression remain largely elusive. We have demonstrated the high expression levels of CDKL3 in OS human specimens and comprehensively investigated the role of CDKL3 in promoting OS progression both in vitro and in vivo. We found that CDKL3 regulates Akt activation and its downstream effects, including cell growth and autophagy. The up-regulation of CDKL3 in OS specimens appeared to be associated with Akt activation and shorter overall patient survival (P = 0.003). Our findings identify CDKL3 as a critical regulator that stimulates OS progression by enhancing Akt activation. CDKL3 represents both a biomarker for OS prognosis, and a potential therapeutic target in precision medicine by targeting CDKL3 to treat Akt hyper-activated OS.
Collapse
Affiliation(s)
- Aina He
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China .,Department of Urology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Lanjing Ma
- College of Life and Health Sciences, Northeastern University, Shenyang, PR China
| | - Yujing Huang
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Haijiao Zhang
- College of Life and Health Sciences, Northeastern University, Shenyang, PR China
| | - Wei Duan
- School of Medicine and Centre for Molecular and Medical Research, Deakin University, Waurn Ponds, Victoria, Australia
| | - Zexu Li
- College of Life and Health Sciences, Northeastern University, Shenyang, PR China
| | - Teng Fei
- College of Life and Health Sciences, Northeastern University, Shenyang, PR China
| | - Junqing Yuan
- Department of Pathology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Hao Wu
- Department of Vascular Biology, Boston Children's Hospital, Boston, MA, USA
| | - Liguo Liu
- Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yueqing Bai
- Department of Pathology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Wentao Dai
- Shanghai Center for Bioinformation Technology and Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai Industrial Technology Institute, Shanghai, PR China
| | - Yonggang Wang
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Hongtao Li
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Yong Sun
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Yaling Wang
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Chunyan Wang
- Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Ting Yuan
- Department of Orthopedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Qingcheng Yang
- Department of Orthopedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, PR China
| | - Songhai Tian
- Department of Urology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Min Dong
- Department of Urology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Ren Sheng
- College of Life and Health Sciences, Northeastern University, Shenyang, PR China
| | - Dongxi Xiang
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA .,Department of Medicine, Harvard Medical School, Boston, MA, USA.,Shanghai Research Center of Biliary Tract Disease Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
Zhang J, Su G, Tang Z, Wang L, Fu W, Zhao S, Ba Y, Bai B, Yue P, Lin Y, Bai Z, Hu J, Meng W, Qiao L, Li X, Xie X. Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3. Front Physiol 2018; 9:234. [PMID: 29615928 PMCID: PMC5870041 DOI: 10.3389/fphys.2018.00234] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 03/02/2018] [Indexed: 01/03/2023] Open
Abstract
Curcumol is the major component extracted from root of Rhizoma Curcumae. Recent studies have shown that curcumol exerts therapeutic effects against multiple conditions, particularly cancers. However, the therapeutic role and mechanism of curcumol against cholangiocarcinoma cells are still unclear. In our current research, we tested the effect of curcumol in cholangiocarcinoma cells, and using two-dimensional electrophoresis, proteomics and bioinformatics, we identified cyclin-dependent kinase like 3 (CDKL3) as a potential target for curcumol. We have demonstrated that curcumol can evidently suppress growth and migration of cholangiocarcinoma cells. Furthermore, curcumol could significantly block the cell cycle progression of the cholangiocarcinoma cells. These effects could be largely attributed to the inhibition of CDKL3 by curcumol. Further studies have recapitulated the oncogenic role of CDKL3 in that knockdown of CDKL3 by lentiviral mediated transfection of shRNA against CDKL3 also led to a significant inhibition on cell proliferation, migration, invasion, and cell cycle progression. Given the high level of CDKL3 expression in human cholangiocarcinoma tissues and cell lines, we speculated that CDKL3 may constitute a potential biological target for curcumol in cholangiocarcinoma.
Collapse
Affiliation(s)
- Jinduo Zhang
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Gang Su
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China
| | - Zengwei Tang
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Li Wang
- School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China.,School of Stomatology, Lanzhou University, Lanzhou, China
| | - Wenkang Fu
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Sheng Zhao
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China
| | - Yongjiang Ba
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Bing Bai
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Ping Yue
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Yanyan Lin
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Zhongtian Bai
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China.,The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China
| | - Jinjing Hu
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Wenbo Meng
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Special Minimally Invasive Surgery, The First Hospital of Lanzhou University, Lanzhou, China.,School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China
| | - Liang Qiao
- Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW, Australia
| | - Xun Li
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,Gansu Province Institute of Hepatopancreatobiliary, Lanzhou, China.,Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China.,The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China
| | - Xiaodong Xie
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.,School of Basic Medical Sciences, Institute of Genetics, Lanzhou University, Lanzhou, China
| |
Collapse
|
5
|
Jaluria P, Betenbaugh M, Konstantopoulos K, Shiloach J. Enhancement of cell proliferation in various mammalian cell lines by gene insertion of a cyclin-dependent kinase homolog. BMC Biotechnol 2007; 7:71. [PMID: 17945021 PMCID: PMC2164945 DOI: 10.1186/1472-6750-7-71] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2007] [Accepted: 10/18/2007] [Indexed: 12/01/2022] Open
Abstract
Background Genomics tools, particularly DNA microarrays, have found application in a number of areas including gene discovery and disease characterization. Despite the vast utility of these tools, little work has been done to explore the basis of distinct cellular properties, especially those important to biotechnology such as growth. And so, with the intent of engineering cell lines by manipulating the expression of these genes, anchorage-independent and anchorage-dependent HeLa cells, displaying markedly different growth characteristics, were analyzed using DNA microarrays. Results Two genes, cyclin-dependent kinase like 3 (cdkl3) and cytochrome c oxidase subunit (cox15), were up-regulated in the faster growing, anchorage-independent (suspension) HeLa cells relative to the slower growing, anchorage-dependent (attached) HeLa cells. Enhanced expression of either gene in the attached HeLa cells resulted in elevated cell proliferation, though insertion of cdkl3 had a greater impact than that of cox15. Moreover, flow cytometric analysis indicated that cells with an insert of cdkl3 were able to transition from the G0/G1 phases to the S phase faster than control cells. In turn, expression of cox15 was seen to increase the maximum viable cell numbers achieved relative to the control, and to a greater extent than cdkl3. Quantitatively similar results were obtained with two Human Embryonic Kidney-293 (HEK-293) cell lines and a Chinese Hamster Ovary (CHO) cell line. Additionally, HEK-293 cells secreting adipocyte complement-related protein of 30 kDa (acrp30) exhibited a slight increase in specific protein production and higher total protein production in response to the insertion of either cdkl3 or cox15. Conclusion These results are consistent with previous studies on the functionalities of cdkl3 and cox15. For instance, the effect of cdkl3 on cell growth is consistent with its homology to the cdk3 gene which is involved in G1 to S phase transition. Likewise, the increase in cell viability due to cox15 expression is consistent with its role in oxidative phosphorylation as an assembly factor for cytochrome c oxidase and its involvement removing apoptosis-inducing oxygen radicals. Collectively, the present study illustrates the potential of using microarray technology to identify genes influential to specific cellular processes with the possibility of engineering cell lines as desired to meet production needs.
Collapse
Affiliation(s)
- Pratik Jaluria
- National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Biotechnology Unit, Building 14A, Room 170, Bethesda, MD 20892, USA.
| | | | | | | |
Collapse
|